Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma.

2009-03-28

Lee, S T

Ghanem, M

Herbertson, R A

Berlangieri, Salvatore U

Byrne, Amanda J

Tabone, K

Mitchell, Paul L R

Knight, Simon R

Feigen, Malcolm

Scott, Andrew M

Journal Article

10.1007/s11307-009-0203-6

To evaluate prognostic value of integrated 2-deoxy-2-[F-18]fluoro-D: -glucose-positron emission tomography/computed tomography (FDG-PET/CT) and correlate histopathological subtype with maximum standardized uptake value (SUV(max)) and survival in patients with malignant mesothelioma (MM).Retrospective review of FDG-PET/CT scans, with derivation of SUV(max) of FDG-avid lesions, was performed in patients with biopsy-proven MM. Clinical follow-up and Kaplan-Meier survival analysis was performed.Forty-six patients (37 M:9 F; mean age 61 years) with MM had a FDG-PET/CT scan in a 30-month period. Follow-up was available on 44/46 (96%) patients. Metastatic disease was detected in 9/46 (20%) patients on FDG-PET/CT, where 8/9 were previously undetected. Better survival was found in patients without metastases (p value < 0.05). Mean SUV(max) of primary pleural lesions in patients with metastatic disease was significantly higher than in patients without metastatic disease (p value < 0.05). Progression-free survival was significantly better in the epithelioid histology group compared to the biphasic group (p value 0.015).Detection of extrathoracic metastases on FDG-PET/CT and nonepithelioid histopathology are poor prognostic indicators in patients with MM.

link

Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging 2009; 11(6): 473-9

Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging